Competing risk model for prognostic comparison between clear cell type and common type hepatocellular carcinoma: A population-based propensity score matching study.
clear cell carcinoma
competing risk model
hepatocellular carcinoma
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
08
08
2022
received:
11
03
2022
accepted:
24
02
2023
medline:
30
5
2023
pubmed:
20
3
2023
entrez:
19
3
2023
Statut:
ppublish
Résumé
Clear cell type hepatocellular carcinoma (HCC) is an uncommon neoplasm with an ambivalent prognosis compared to common type HCC. First, patients with clear cell or common type HCC were enrolled from the Surveillance, Epidemiology, and End Results (SEER) database, and their demographic and clinical characteristics were identified. Next, overall survival (OS), disease-specific survival (DSS), and subgroup analysis of the two types of HCC were performed. Next, we utilized a competing risk model to focus on cancer-caused death. Finally, propensity score matching (PSM) was employed to reduce the confounding factors based on the histopathological type, and sensitivity analysis was conducted. A total of 205 cases of clear cell type HCC and 29,954 cases of common type HCC were enrolled in our study. Patients with clear cell type HCC were older and predominantly female than those with common type HCC. OS and DSS were not significantly different between the two groups, and histopathological type was not a prognostic factor of HCC, as verified by the competing risk model. Patient characteristics adjusted by PSM and sensitivity analysis confirmed this conclusion. In subgroup analysis, patients with clear cell type HCC at grade III ~ IV and with lymph nodes metastasis had a better prognosis compared to common type HCC. This study revealed that the prognosis of clear cell type HCC is similar to common type HCC. Tumor differentiation grade and status of lymph node metastasis affect the prognosis of HCC.
Sections du résumé
BACKGROUND
Clear cell type hepatocellular carcinoma (HCC) is an uncommon neoplasm with an ambivalent prognosis compared to common type HCC.
METHODS
First, patients with clear cell or common type HCC were enrolled from the Surveillance, Epidemiology, and End Results (SEER) database, and their demographic and clinical characteristics were identified. Next, overall survival (OS), disease-specific survival (DSS), and subgroup analysis of the two types of HCC were performed. Next, we utilized a competing risk model to focus on cancer-caused death. Finally, propensity score matching (PSM) was employed to reduce the confounding factors based on the histopathological type, and sensitivity analysis was conducted.
RESULTS
A total of 205 cases of clear cell type HCC and 29,954 cases of common type HCC were enrolled in our study. Patients with clear cell type HCC were older and predominantly female than those with common type HCC. OS and DSS were not significantly different between the two groups, and histopathological type was not a prognostic factor of HCC, as verified by the competing risk model. Patient characteristics adjusted by PSM and sensitivity analysis confirmed this conclusion. In subgroup analysis, patients with clear cell type HCC at grade III ~ IV and with lymph nodes metastasis had a better prognosis compared to common type HCC.
CONCLUSIONS
This study revealed that the prognosis of clear cell type HCC is similar to common type HCC. Tumor differentiation grade and status of lymph node metastasis affect the prognosis of HCC.
Identifiants
pubmed: 36934433
doi: 10.1002/cam4.5773
pmc: PMC10225237
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10406-10422Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Kaohsiung J Med Sci. 2004 Feb;20(2):78-82
pubmed: 15481555
World J Gastroenterol. 2010 Feb 14;16(6):764-9
pubmed: 20135727
Hepatol Res. 2008 Mar;38(3):291-9
pubmed: 17877725
Chin J Cancer Res. 2018 Jun;30(3):364-372
pubmed: 30046230
Pathol Int. 1996 Jul;46(7):503-9
pubmed: 8870006
Medicine (Baltimore). 2017 Mar;96(12):e6452
pubmed: 28328858
J Natl Cancer Inst. 2018 Aug 1;110(8):825-830
pubmed: 30011032
Dig Dis Sci. 1998 Jan;43(1):33-8
pubmed: 9508531
Histopathology. 2001 Mar;38(3):225-31
pubmed: 11260303
Cancer. 1979 Nov;44(5):1677-83
pubmed: 227575
Cancer. 1990 Jan 1;65(1):130-4
pubmed: 2152849
J Am Geriatr Soc. 2010 Apr;58(4):783-7
pubmed: 20345862
Med Sci Monit. 2020 Jan 23;26:e919789
pubmed: 31969554
Cancer. 2002 Jun 15;94(12):3307-12
pubmed: 12115365
Clin Liver Dis. 2015 May;19(2):223-38
pubmed: 25921660
Onco Targets Ther. 2016 Jul 06;9:4129-35
pubmed: 27462167
Spine (Phila Pa 1976). 2010 Jun 15;35(14):1377-86
pubmed: 20505561
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Hepatobiliary Pancreat Dis Int. 2017 Dec 15;16(6):570-594
pubmed: 29291777
N Engl J Med. 2019 Apr 11;380(15):1450-1462
pubmed: 30970190
Ann Surg Oncol. 2011 Jul;18(7):1955-63
pubmed: 21240562
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Cancer Med. 2023 May;12(9):10406-10422
pubmed: 36934433
Nat Rev Gastroenterol Hepatol. 2022 Apr;19(4):257-273
pubmed: 35022608
Future Oncol. 2022 Feb;18(5):543-552
pubmed: 34878322
World J Gastroenterol. 2019 Apr 14;25(14):1653-1665
pubmed: 31011252